WO2007028145A3 - Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system - Google Patents
Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system Download PDFInfo
- Publication number
- WO2007028145A3 WO2007028145A3 PCT/US2006/034467 US2006034467W WO2007028145A3 WO 2007028145 A3 WO2007028145 A3 WO 2007028145A3 US 2006034467 W US2006034467 W US 2006034467W WO 2007028145 A3 WO2007028145 A3 WO 2007028145A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reduce
- activity
- nervous system
- central nervous
- methods
- Prior art date
Links
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 title abstract 3
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 title abstract 3
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000000736 Amenorrhea Diseases 0.000 abstract 1
- 206010001928 Amenorrhoea Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 231100000540 amenorrhea Toxicity 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000009229 glucose formation Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
- 229940039781 leptin Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides pharmaceutical compositions and methods for administration to the central nervous system to reduce protein tyrosine phosphatase 1B (PTP1B) activity, reduce peripheral glucose concentrations, reduce glucose production, reduce lipid, triglyceride and/or cholesterol levels (e.g., in blood, plasma or serum), and/or food intake, and/or to treat a metabolic disorder such as diabetes mellitus (e.g., type I or type II), metabolic syndrome, hyperglycemia, insulin resistance, glucose intolerance and/or obesity, and/or to treat disorders such as leptin resistance, gonadotropin deficiency, heart failure, ischemia, atherosclerosis, coronary artery disease, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, familial lipoprotein lipase deficiency, hypertension, amenorrhea, cancer (including tumor forming cancers), neurodegenerative disease, and/or polycystic ovary syndrome. Also provided is a delivery device comprising a pharmaceutical composition of the invention.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71406205P | 2005-09-02 | 2005-09-02 | |
| US60/714,062 | 2005-09-02 | ||
| US78596506P | 2006-03-24 | 2006-03-24 | |
| US60/785,965 | 2006-03-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007028145A2 WO2007028145A2 (en) | 2007-03-08 |
| WO2007028145A3 true WO2007028145A3 (en) | 2007-10-11 |
Family
ID=37809651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2006/034467 WO2007028145A2 (en) | 2005-09-02 | 2006-09-01 | Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007028145A2 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009001043A (en) | 2006-08-08 | 2009-02-06 | Sanofi Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use. |
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| US8242092B2 (en) | 2008-02-05 | 2012-08-14 | Brent Townshend | Protein tyrosine phosphatase inhibitors |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| KR20120060207A (en) | 2009-08-26 | 2012-06-11 | 사노피 | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| US8586624B2 (en) | 2009-12-16 | 2013-11-19 | N30 Pharmaceuticals, Inc. | Thiophene inhibitors of S-nitrosoglutathione reductase |
| WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003041729A1 (en) * | 2001-09-26 | 2003-05-22 | Albert Einstein College Of Medicine Of Yeshiva University | Ptp1b inhibitors and ligands |
| US6602867B1 (en) * | 1999-01-12 | 2003-08-05 | Abbott Laboratories | Triazole compounds with dopamine-D3-receptor affinity |
| US20040186124A1 (en) * | 2003-01-06 | 2004-09-23 | Wynne Graham Michael | (2-carboxamido)(3-amino)thiophene compounds |
| US20050124656A1 (en) * | 2002-01-29 | 2005-06-09 | Applied Research Systems Ars | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) |
-
2006
- 2006-09-01 WO PCT/US2006/034467 patent/WO2007028145A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602867B1 (en) * | 1999-01-12 | 2003-08-05 | Abbott Laboratories | Triazole compounds with dopamine-D3-receptor affinity |
| WO2003041729A1 (en) * | 2001-09-26 | 2003-05-22 | Albert Einstein College Of Medicine Of Yeshiva University | Ptp1b inhibitors and ligands |
| US20050124656A1 (en) * | 2002-01-29 | 2005-06-09 | Applied Research Systems Ars | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) |
| US20040186124A1 (en) * | 2003-01-06 | 2004-09-23 | Wynne Graham Michael | (2-carboxamido)(3-amino)thiophene compounds |
Non-Patent Citations (3)
| Title |
|---|
| GIROUX ET AL.: "Nassal Drug deposition, controlled particle dispersion: Applying vertical flow to optimize hasal drug deposition", DRUG DELIVERY TECHNOLOGY, vol. 5, no. 3, March 2005 (2005-03-01), pages 44 - 49 * |
| IVERSEN ET AL.: "Structure-based Design of a Low Molecular Weight, Nonphosphorus, Nonpeptide, and Highly Selective Inhibitor of Protein-tyrosine Phosphatase 1B", J. BIOL. CHEM., vol. 275, no. 14, April 2000 (2000-04-01), pages 10300 - 10307, XP002902040, DOI: doi:10.1074/jbc.275.14.10300 * |
| PETTI ET AL.: "Temporal quantitation of mutant kit tyrosine signaling attenuated by a novel thiophene kinase inhibitor OSI-930", MOL. CANCER, vol. 4, June 2005 (2005-06-01), pages 1188 - 1197 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007028145A2 (en) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007028145A3 (en) | Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system | |
| BR0318046A (en) | Hydroxyl Compounds and Cholesterol Control Compositions and Related Jobs | |
| Volpe et al. | Cellular death, reactive oxygen species (ROS) and diabetic complications | |
| Davidson et al. | Comparative effects of lipid-lowering therapies | |
| Kuivenhoven et al. | Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia | |
| Bustanji et al. | Pancreatic lipase inhibition activity of trilactone terpenes of Ginkgo biloba | |
| Chen et al. | Erinacine S, a rare sesterterpene from the mycelia of Hericium erinaceus | |
| WO2015200078A8 (en) | Fatty acids and their use in conjugation to biomolecules | |
| Yan et al. | Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus | |
| Petyaev | State of the art paper improvement of hepatic bioavailability as a new step for the future of statin | |
| WO2007002365A3 (en) | Modulation of amino acid metabolism in the hypothalamus | |
| Wu et al. | In vivo pharmacodynamic and pharmacokinetic effects of metformin mediated by the gut microbiota in rats | |
| WO2008078176A9 (en) | Methods, compounds, and compositions for treating metabolic disorders and diabetes | |
| Wu et al. | Neohesperidin exerts lipid-regulating effects in vitro and in vivo via fibroblast growth factor 21 and AMP-activated protein kinase/sirtuin type 1/peroxisome proliferator-activated receptor gamma coactivator 1α signaling axis | |
| WO2006031293A3 (en) | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia | |
| Siddiqui et al. | Saroglitazar, a dual PPAR α/γ agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis | |
| Cheng et al. | Ursolic acid alleviates lipid accumulation by activating the AMPK signaling pathway in vivo and in vitro | |
| EP1968561B8 (en) | Treatment of diabetic nephropathy | |
| Cotugno et al. | Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation | |
| Lavasani et al. | Study of the pharmacokinetic changes of Tramadol in diabetic rats | |
| Pari et al. | Antihyperlipidemic effect of coumarin in experimental type 2 diabetic rats | |
| Sheik et al. | Anti-hyperglycemic, anti-hyperlipidemic, and anti-inflammatory effect of the drug Guggulutiktaka ghrita on high-fat diet-induced obese rats | |
| BRPI0406772A (en) | Compound, processes for preparing an amino acid phenolic ether and compound, pharmaceutical composition, methods for reducing glucose, free fatty acids, cholesterol, and plasma triglyceride levels, for treating obesity, autoimmune diseases, inflammation, immune disease, and a disorder associated with insulin resistance, and intermediate | |
| Abdel-Magid | GPR40 receptor agonists for the treatment of type 2 diabetes and related diseases | |
| Rozema et al. | Characterization of glucocerebrosides and the active metabolite 4, 8-sphingadienine from Arisaema amurense and Pinellia ternata by NMR and CD spectroscopy and ESI-MS/CID-MS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06802934 Country of ref document: EP Kind code of ref document: A2 |